143 related articles for article (PubMed ID: 31847617)
1. Development of a novel
Zhang J; Penny J; Lu JR
Int J Food Sci Nutr; 2020 Aug; 71(5):549-562. PubMed ID: 31847617
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
[TBL] [Abstract][Full Text] [Related]
3. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
4. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
[TBL] [Abstract][Full Text] [Related]
5. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
6. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
Han LW; Gao C; Mao Q
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Sodhi JK; Liu S; Benet LZ
Pharm Res; 2020 Sep; 37(10):208. PubMed ID: 32996065
[TBL] [Abstract][Full Text] [Related]
8. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.
Beéry E; Rajnai Z; Abonyi T; Makai I; Bánsághi S; Erdő F; Sziráki I; Herédi-Szabó K; Kis E; Jani M; Márki-Zay J; Tóth GK; Krajcsi P
Drug Metab Pharmacokinet; 2012; 27(3):349-53. PubMed ID: 22790065
[TBL] [Abstract][Full Text] [Related]
10. Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Pharmacol Res Perspect; 2020 Feb; 8(1):e00544. PubMed ID: 31988753
[TBL] [Abstract][Full Text] [Related]
11. The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.
Ellis K; Marlin JW; Taylor TA; Fitting S; Hauser KF; Rice G; McRae M
J Pharm Pharmacol; 2015 Feb; 67(2):178-88. PubMed ID: 25557407
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
14. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
15. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
16. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
17. Cellular Uptake and Transport Characteristics of FL118 Derivatives in Caco-2 Cell Monolayers.
Zhou Y; Hu W; Zhang X; Wang Y; Zhuang W; Li F; Li Q
Chem Pharm Bull (Tokyo); 2021; 69(11):1054-1060. PubMed ID: 34719586
[TBL] [Abstract][Full Text] [Related]
18. Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo).
Chen Y; Zhao YH; Jia XB; Hu M
Pharm Res; 2008 Sep; 25(9):2190-9. PubMed ID: 18459036
[TBL] [Abstract][Full Text] [Related]
19. A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in Caco-2 model.
Shah D; Paruchury S; Matta M; Chowan G; Subramanian M; Saxena A; Soars MG; Herbst J; Haskell R; Marathe P; Mandlekar S
Drug Metab Lett; 2014; 8(2):109-18. PubMed ID: 25429513
[TBL] [Abstract][Full Text] [Related]
20. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.
Tupova L; Ceckova M; Ambrus C; Sorf A; Ptackova Z; Gaborik Z; Staud F
Drug Metab Dispos; 2019 Sep; 47(9):954-960. PubMed ID: 31266750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
